Scientific articles authored by Novo Nordisk
The information you can search here is retrieved via the database Current Contents®, covering 95% of publications within the life science area. Only articles authored by at least one researcher from Novo Nordisk are included in the search results. The database provides easy access to tables of contents, abstracts, bibliographic information, and abstracts from the most recently published issues of leading scholarly journals.
Prevention of haemarthrosis in a murine model of acute joint bleeding
Author(s): Valentino LA ; Hakobyan N ; Kazarian T ; Sorensen BB ; Tranholm M
Valentino LA, Rush Univ, Med Ctr, Dept Pediat, RUSH Hemophilia & Thrombophilia Ctr, 1653 W Congress Pkwy, Chicago, IL 60612 USA, email@example.com
Haemophilia 2009, Vol. 15, pg. 314-319
Preservation of normal joint function in patients with haemophilia is a goal of modern therapy. Regular injections of anti-haemophilic factor concentrate reduce the risk of joint bleeding, the optimal regimen for which remains under investigation. The goals of the experiment described here are: (i) to assess the capacity of a murine model of severe haemophilic arthropathy to predict the likelihood of success of a test product to prevent joint bleeding and the complications that follow and (ii) to compare the effectiveness of recombinant human activated factor VII (rFVIIa) to recombinant human factor VIII (rFVIII) to prevent acute joint bleeding in the mouse model of haemarthrosis. Mice lacking expression of FVIII received a single intravenous injection of human rFVIII (280 U kg(-1)), rFVIIa (10 mg kg(-1)) or vehicle prior to blunt trauma injury to the knee joint. Mice receiving rFVIII and rFVIIa developed less injury-induced joint bleeding, swelling and loss of range of motion compared to mice pretreated with vehicle. Despite the reduction in clinical symptoms, synovial hyperplasia was evident in all groups after 7 days although less pronounced in mice receiving rFVIII and rFVIIa. The data under these experimental conditions demonstrate: (i) that this model can be used to evaluate novel therapies designed to prevent joint bleeding (prophylaxis) and (ii) both rFVIII and rFVIIa reduced acute haemarthrosis but did not completely prevent synovitis, the sequelae of blood induced joint injury.Back